...
首页> 外文期刊>Journal of Pharmacy and Bioallied Sciences >Assessing adherence and persistence to non-vitamin K antagonist oral anticoagulants (NOACs) among patients with atrial fibrillation in tertiary-care referral centers in Malaysia
【24h】

Assessing adherence and persistence to non-vitamin K antagonist oral anticoagulants (NOACs) among patients with atrial fibrillation in tertiary-care referral centers in Malaysia

机译:在马来西亚初级护理转诊中心的心房颤动患者中评估对非维生素K拮抗剂口腔抗凝血剂(NOAC)的粘附和持续性

获取原文
           

摘要

Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran and rivaroxaban, are now available for stroke prevention in patients with atrial fibrillation (AF) and are often clinically preferred over vitamin K antagonists (VKAs), such as warfarin. Data describing adherence and persistence to NOACs in real-life clinical practice in Malaysia are scarce. This study aimed to assess adherence and persistence to NOACs in patients with AF in two tertiary-care referral centers: Hospital Kuala Lumpur (HKL) and Hospital Serdang (HSDG). Materials and Methods: This was a retrospective cohort study that included all patients with AF who were treated with NOACs (dabigatran or rivaroxaban) in HKL and HSDG. Data were obtained from medical records and pharmacy databases. Adherence was assessed using proportion of days covered (PDC) over a 1-year duration. High adherence was defined as PDC ≥80%. A gap of 60 days between two consecutive refills was used to define non-persistence. Result: There were 281 patients who met the inclusion criteria, with 54.1% (n = 152) male. There were 75.1% (n = 211) patients on dabigatran and others on rivaroxaban. Only 66.9% (n = 188) of patients achieved high adherence with PDC ≥80% and 69.8% (n = 196) were persistence with 60-day gap over 12 months. Adherence and persistence were both influenced by treatment center, whereas polypharmacy only influenced adherence. Conclusion: Overall adherence and persistence to NOACs were suboptimal and varied between treatment centers, potentially due to institution-specific administrative and clinical practice differences. Clinical care and outcomes can potentially be optimized by identifying factors affecting adherence and persistence and by implementing interventions to improving them.
机译:简介:非维生素K拮抗剂口腔抗凝血剂(NOAC),如Dabigatran和Rivaroxaban,现在可以用于心房颤动(AF)的患者中卒中预防,并且通常在维生素K拮抗剂(VKAS)上临床优选,例如华法林。描述在马来西亚现实生活临床实践中脱落的遵守和持续存在的数据是稀缺的。该研究旨在评估两次第三级护理转诊中心的AF患者的Noacs:吉隆坡(HKL)和医院Serdang(HSDG)的医院持久性。材料和方法:这是一个回顾性队列研究,包括所有患有HKL和HSDG的NOACS(Dabigatran或Rivaroxaban)治疗的AF的患者。数据是从医疗记录和药房数据库获得的。在1年期间使用(PDC)的比例评估依从性评估。高粘附性定义为PDC≥80%。在两个连续的再填充之间的间隙> 60天用于定义非持久性。结果:有281名患者符合纳入标准,男性为54.1%(n = 152)。 Dabigatran和Rivaroxaban的其他人有75.1%(n = 211)患者。只有66.9%(n = 188)的患者实现了高粘附性,PDC≥80%,69.8%(n = 196)持续存在> 60天差距超过12个月。依从性和持续性既受到治疗中心的影响,而多药只会影响依从性。结论:整体依从性和持续性对Noacs的次优和治疗中心之间不同,可能是由于机构特异性的行政和临床实践差异。临床护理和结果可能通过确定影响遵守和持久性的因素以及实施干预措施来改善它们来进行优化。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号